Today, I'd like to provide an update on the coronavirus, including the economic and market implications. After several weeks of improvement on the medical front, we’re starting to see modest deterioration as the country reopens. Case counts and positive test rates are back to early March levels, while hospitalizations and death rates have stabilized. While the short-term risks are real, we do have a better outlook for the next two to three months. At that point, between vaccinations and existing exposure, we should be at or close to herd immunity.

Today, I'd like to provide an update on the coronavirus, including the economic and market implications. The medical situation continues to improve, as the vaccination campaign moves forward. Still, case growth remains above the levels seen between the second and third waves, and positive rates have not improved in weeks. We still have a very real pandemic on our hands.

Today, I'd like to provide an update on the coronavirus, including the economic and market implications. On the medical front, the stats have been getting better for the past two months, with case growth and hospitalizations down. That’s the good news. The bad news is that we are now at levels we saw at the peak of the second wave. And with some states starting to reopen and ending mandatory mask wearing, there are real things to worry about in the months ahead.

Markets climbed in February, although they faced some turbulence on a spike in interest rates. While markets were choppy, the medical news improved. New cases and hospitalizations dropped, and vaccinations more than doubled. On the economic front, unemployment remains high, but companies are hiring again. Plus, stimulus payments hit bank accounts, and consumer confidence is moving up.

Today I'd like to provide an update on the coronavirus, including the economic and market implications. On the medical front, we appear to be well past the peak of the third wave, with daily infection rates and hospitalizations down. A more contagious variant of the virus could start another wave of infections, although there are no signs of that happening yet.

Today, I'd like to provide an update on the coronavirus, including the economic and market implications. On the medical front, new daily infection rates and hospitalizations were down, and we saw improvement in positive testing rates. Although the threat of a more contagious variant of the virus remains, substantial progress on vaccinations should help offset that risk.

Most developed markets were down slightly in January, including the Dow and S&P 500 in the U.S., as well as developed markets abroad. Despite the month's weak numbers, markets remain near all-time highs. On the economic front, layoffs were high and retail spending dropped. But with federal stimulus payments, consumer confidence has begun to recover, boosting higher-frequency spending data.

Today, I'd like to provide an update on the coronavirus, including the economic and market implications. On the medical front, the holiday infection surges have faded. Case growth remains high, but we saw improvements in positive testing rates, as well as a decline in hospitalizations. Absent a sudden appearance of the more infectious strain of the virus, we are likely to see more progress in the next couple of weeks as vaccine deployment accelerates.

Today, I'd like to provide an update on the coronavirus, including the economic and market implications. On the medical front, holiday travel effects have kept infection growth at high levels, and positive results also moved to new highs. Still, we should see vaccinations ramp up by the end of the month, and we could approach herd immunity as soon as June.

December was a great month for the markets, with gains across the board. Unfortunately, we saw rising economic damage. Job growth dropped, and layoffs rose. Consumer confidence and spending also declined as the medical risks drove governmental shutdowns. Still, business confidence and spending were solid, and December's federal stimulus bill should help revive consumer demand.